Abstract
Abstract
Background
Medical cannabis, legalized in many countries, remains illegal in France. Despite an experiment in the medical use of cannabis that began in March 2021 in France, little is known about the factors associated with the use of cannabis for self-medication among adults.
Methods
Data came from the French TEMPO cohort and were collected between December 2020 and May 2021. Overall, 345 participants aged 27–47 were included. Cannabis for self-medication was defined using the following questions: ‘Why do you use cannabis?’ and ‘In what form do you use cannabis?’. The penalized regression method “Elastic net” was used to determine factors associated with the use of cannabis for self-medication, with the hypothesis that it is mainly used for pain in individuals who have already used cannabis.
Results
More than half of the participants reported having ever used cannabis (58%). Only 10% used it for self-declared medical reasons (n = 36). All self-medication cannabis users, except one, were also using cannabis for recreational purposes. The main factors associated with cannabis use for self-medication vs. other reasons included cannabis use trajectories, the presence of musculoskeletal disorders, tobacco smoking, and parental divorce.
Conclusions
Engaging in cannabis use during adolescence or early adulthood may increase the likelihood of resorting to self-medication in adulthood. Due to the propensity of individuals with cannabis use during adolescence to resort to uncontrolled products for self-medication, this population should be more systematically targeted and screened for symptoms and comorbidities that may be associated with cannabis use.
Funder
Institut pour la Recherche en Santé Publique
Alliance Nationale pour les Sciences de la Vie et de la Santé
Agence Nationale de la Recherche
Mission Interministérielle de Lutte Contre les Drogues et les Conduites Addictives
Institut National Du Cancer
Pfizer Foundation
IRESP
Publisher
Springer Science and Business Media LLC
Reference67 articles.
1. Abuhasira R, Shbiro L, Landschaft Y. Medical use of cannabis and cannabinoids containing products – Regulations in Europe and North America. Eur J Intern Med. 2018;49:2–6.
2. Achenbach TM. DSM-Oriented Guide for the Achenbach System of Empirically Based Assessment (ASEBA®) An Integrated System of Multi-Informant Assessment; 2015. Available from: https://aseba.org/wp-content/uploads/DSM-Oriented-Guide-for-the-ASEBA.pdf. Cited 2022 Jun 7.
3. Agence Nationale de Sécurité du Médicaments et des produits de santé (ANSM). Cadre et mise en oeuvre de l’expérimentation du cannabis médical [Framework and implementation of medical cannabis experimentation] ; 2021. Available from: https://ansm.sante.fr/dossiers-thematiques/cannabis-a-usage-medical/cadre-et-mise-en-oeuvre-de-lexperimentation-du-cannabis-medical.
4. Aljandaleh H, Bolze C, El-Khoury Lesueur F, Melchior M, Mary-Krause M. Factors Associated with Electronic Cigarette Use among Young Adults: The French “Trajectoires EpidéMiologiques en POpulation” (TEMPO) Cohort Study. Subst Use Misuse. 2020;55(6):964–72.
5. Azcarate PM, Zhang AJ, Keyhani S, Steigerwald S, Ishida JH, Cohen BE. Medical reasons for marijuana use, forms of use, and patient perception of physician attitudes among the US Population. J Gen Intern Med. 2020;35(7):1979–86.